KRAS mutation did not worsen intracranial control after SRS for NSCLC brain metastases
KRAS-mutant and wild-type NSCLC showed similar intracranial control after SRS, while higher radiation dose predicted better outcomes.
Tag
brain-metastases
Low-dose brain exposure diverged sharply between SRT platforms as metastasis number increased
CyberKnife best contained low-dose spread at high lesion burdens but required substantially longer treatment than faster VMAT strategies.
SMART planning reduced memory-circuit dose during SRS for ≥10 brain metastases
SMART reduced mean memory-circuit dose from 2.9 to 1.8 Gy while maintaining greater than 95% target coverage.
Brain metastasis SRS fractionation varied widely across Turkish radiation oncologists
Tumor volume and OAR proximity drove brain metastasis fractionation, while preoperative SRS showed a substantial preference-to-practice gap.
SRT did not improve survival over whole-brain radiotherapy after matching in SCLC
After propensity matching, SRT did not improve survival over WBRT, while adding a boost showed a non-robust intracranial control signal.
ESTRO review supports selective CNS reirradiation but highlights cumulative-dose limits
ESTRO supports individualized reirradiation for selected recurrent brain tumors, with cumulative dose, target volume and critical structures determining feasibility.
MR-only CyberKnife planning achieved near-equivalent dosimetry for brain metastases
Synthetic CT reproduced CyberKnife target dosimetry closely and enabled submillimetre translational image guidance, although rotational errors were more variable.
Individual target optimization reduced brain dose in single-isocenter multi-metastasis radiosurgery
Individual target optimization lowered normal-brain V12 and improved dose gradients while maintaining over 99% coverage, at the cost of higher monitor units.
Twenty-two Gy SRS was associated with better brain metastasis control than 20 Gy
Single-fraction 22 Gy SRS achieved higher one-year local control than 20 Gy, although retrospective dose selection creates important confounding.
Submillimetre MLC errors substantially altered HyperArc brain metastasis dose
A 1 mm symmetric MLC closing reduced minimum GTV dose by 25%, while translations caused cumulative target undercoverage.
Preoperative stereotactic radiotherapy shortened brain metastasis treatment without increasing early morbidity
Preoperative SRS/FSRT completed local therapy 22.5 days sooner than postoperative treatment, with similar 30-day morbidity; oncologic outcomes remain pending.
CyberKnife dose models found size-dependent but non-monotonic brain metastasis control
Tumour-size strata showed non-monotonic BED–control relationships, while machine-learning performance remained unvalidated outside a single retrospective centre.
Early neuropsychological care did not improve three-month quality of life in brain metastases
ATHENA did not improve FACT-Br scores at three months, although an exploratory nine-month analysis favoured neuropsychological integration.
Brain metastasis contouring variability depended on lesion and MRI factors
Brain metastasis contours showed generally high agreement, although lesion volume, oedema and magnetic resonance imaging field strength influenced variability.
Late radiation necrosis after stereotactic radiosurgery temporally associated with COVID-19 vaccination
A case report describes pathology-confirmed late radiation necrosis after stereotactic radiosurgery, with radiographic progression temporally associated with repeated COVID-19 vaccination.